Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma

Glioblastoma multiforme (GBM) is the most common and most aggressive primary brain tumor in humans. Systemic immunity against gene therapy vectors has been shown to hamper therapeutic efficacy; however, helper‐dependent high‐capacity adenovirus (HC‐Ad) vectors elicit sustained transgene expression,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2010-08, Vol.88 (2), p.204-213
Hauptverfasser:	Muhammad, A K M G, Puntel, M, Candolfi, M, Salem, A, Yagiz, K, Farrokhi, C, Kroeger, K M, Xiong, W, Curtin, J F, Liu, C, Lawrence, K, Bondale, N S, Lerner, J, Baker, G J, Foulad, D, Pechnick, R N, Palmer, D, Ng, P, Lowenstein, P R, Castro, M G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Adenoviridae - immunology Adjuvants, Immunologic - therapeutic use Animals Behavior, Animal Biological and medical sciences Brain Neoplasms - psychology Brain Neoplasms - therapy Clinical Trials, Phase I as Topic Dose-Response Relationship, Immunologic Gene Dosage Genetic Therapy Genetic Vectors - adverse effects Genetic Vectors - pharmacokinetics Genetic Vectors - therapeutic use Glioblastoma - psychology Glioblastoma - therapy Humans Immunohistochemistry Injections Medical sciences Neoplasm Transplantation Neurology Pharmacology. Drug treatments Rats Survival Analysis Tissue Distribution Transgenes - genetics Tumors of the nervous system. Phacomatoses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!